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Abstract 
Abstract 
Review on t(2;9)(q12;q34), with data on clinics, and 
the genes involved. 
Keywords: chromosome 2; chromosome 9; 
RANBP2; ABL1 
GTG banding showing chromosomes 2 and 9 and the 
derivatives der(2) and der(9). 
Clinics and pathology 
Disease 
Pre-B acute lymphoblastic leukemia 
Epidemiology 
Two cases reported: a 15year-old male (Roberts et 
al., 2012; Roberts et al., 2014) and a 21-month girl 
(Braekeleer et al., 2015). 
Evolution 
Alive 23 months after diagnosis in complete 
remission for one case, unknown for the other. 
Cytogenetics 
The t(2;9)(q12;q34)involves the RANBP2 and 
ABL1 genes. This fusion was first identified by 
RNA-sequencing in a boy with B-cell ALL (Roberts 
et al., 2012). 
Cytogenetics morphological 
t(2;9)(q12;q34) is identified by banding 
cytogenetics. 
Cytogenetics molecular 
FISH with a BCR-ABL probe showed 3 ABL 
signals. To determine the position of the breakpoints 
on chromosome 2, BACs located in bands 2q12.1 to 
2q14.2 were used as probes in FISH experiments.  
A split signal on der(2) and der(9) was found with 
RP11-622D1, RP11-347H10, RP11-259O12, RP11-
348G16 and RP11-953L12. These BAC clones 
overlap the RANBP2 gene and allow refinement of 
the breakpoint to a 25kb region covering the 5' end 
and the first three exons of RANBP2 (figure BAC). 
Genes involved and 
proteins 
RANBP2 (RAN binding protein 2) 
Location 
2q12.3 
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FISH with BACs RP11-953L12 (spectrum green, located in 
2q12 and containing RANBP2) and RP11-83J21 (spectrum 
orange, located in 9q34 and containing the 3' part of ABL1) 
and CEP9 (in aqua) showing one fusion signal on der(2). 
No fusion is detected on der(9) because RP11-83J21 does 
not cover the 5' part of ABL1. 
DNA/RNA 
The RANBP2 (alias NUP358) gene contains 31 
exons, spanning 66 kb. One major transcript with 
several alternative splicing variants is known. 
Protein 
The protein has 3324 amino acids and is the largest 
component of nuclear pore complexes. It contains an 
N-terminal leucine-rich region, four RAN binding 
domains, eight zinc-finger motifs, a SUMO E3 
ligase region and a C-terminal cyclophilin A-like 
domain. A detailed assessment of its functions is 
available elsewhere in the Atlas (Di Cesare E, Lavia 
P. RANBP2 (RAN binding protein 2. 
http://AtlasGeneticsOncology.org/Genes/RANBP2I
D483.html). 
ABL1 (v-abl Abelson murine 
leukemia viral oncogene homolog 1) 
Location 
9q34.12 
DNA/RNA 
The ABL1 gene, spanning a 230kb region at band 
9q34, includes the 5' alternative first exons 1b and 1a 
and ten common exons numbered from 2 to 11. 
Alternative splicing using exons 1b and 1a gives rise 
to mRNA of 7 and 6 kb, respectively. 
Protein 
The ABL1 protein has three SRC homology (SH) 
domains called SH1, SH2 and SH3, of which SH1 
that has tyrosine kinase function.  
The SH2 and SH3 domains are involved in protein-
protein interactions, which regulate the tyrosine 
kinase activity; they are necessary for signal 
transduction function. The ABL1 protein has also 
three nuclear localization signal domains and three 
DNA binding regions and an F-actin binding 
domain. 
Result of the chromosomal 
anomaly 
Hybrid gene 
Description 
The 3' region of ABL1 is translocated on the 5' 
region of RANBP2 on the der(2) and the 3' region of 
RANBP2 is translocated on the 5' region of ABL1 
on der(9). 
Detection 
FISH detection. 
Fusion protein 
Description 
The fusion protein retains the leucine-rich domain, 
including a leucine zipper, located at the N-terminal 
of RANBP2 and the tyrosine kinase domain of the 
ABL1 protein. 
Oncogenesis 
The leucine-rich region of RANBP2 is predicted to 
mediate homo-oligomerization of the fusion protein, 
leading to the activation of the tyrosine kinase of 
ABL1. 
To be noted 
Two other genes are known to fuse to RANBP2 and 
generate in-frame transcripts. These are ALK in 
inflammatory myofibroblastic tumor (Li et al., 
2013;Ma et al., 2003), diffuse large B-cell 
lymphoma (Lee et al., 2014) and myeloid neoplasm 
(Lim et al., 2014;Maesako et al., 2014;Rottgers et al., 
2010) and FGFR1 in myeloproliferative neoplasm 
(Gervais et al., 2013). In all cases, the fusion protein 
includes the leucine zipper portion of RANBP2 and 
the tyrosine kinase domain of the partner protein, 
leading to its activation.  
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